ONCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oncolytics Biotech Inc (ONCY) is not a strong buy at this time for a beginner investor with a long-term strategy. While the stock shows some positive technical indicators and a slight pre-market price increase, the lack of significant trading trends, weak financial performance, and absence of strong catalysts suggest a hold position. The investor may consider monitoring the stock for further developments, especially regarding the FDA meeting and pivotal study alignment.
The MACD histogram is positive at 0.0214, indicating a bullish trend, but it is contracting. RSI is neutral at 59.699, and moving averages are converging, suggesting no strong directional trend. Key resistance levels are at 1.076 and 1.134, while support levels are at 0.889 and 0.831. The stock is trading above the pivot point of 0.982, which is a mildly positive signal.
The company has scheduled a Type C meeting with the FDA to align on a pivotal study for pelareorep in squamous cell anal carcinoma, which could be a significant future catalyst.
The company has no recent news or significant trading trends. Financial performance remains weak, with no revenue growth and negative net income, despite some YoY improvement.
In Q3 2025, the company reported no revenue growth (0.00% YoY). Net income improved YoY by 50.90% to -$14.4M, and EPS increased by 16.67% to -0.14. Gross margin remains at 0, indicating no profitability.
Lake Street analyst Chad Messer lowered the price target from $7 to $5 while maintaining a Buy rating. This reflects a cautious optimism but reduced expectations for the stock's performance.
